secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001104659-24-061146
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel reports Q1 net loss of $2.9M; begins Phase 2 fadraciclib enrollment; secures $8M private placement
--------------------------------------------------------------------------------

- Net loss of $2.9M for Q1 2024 compared to $5.8M in Q1 2023; R&D expenses fell to $2.8M from $5.7M.
- Pro forma cash $9.9M including $8M private placement proceeds; actual cash $2.8M at March 31, 2024.
- Phase 2 proof-of-concept study for oral fadraciclib enrolling patients; final Phase 1 data to be presented at ASCO 2024.
- $8.0 million private placement completed under Nasdaq rules, bolstering balance sheet.
- Net cash used in operations was $0.5M in Q1 2024 vs $6.9M in Q1 2023; company expects funding into Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465924061146/0001104659-24-061146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465924061146/tm2414455d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-061146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer